- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Head up display.
Displaying page 1 of 1.
EudraCT Number: 2022-000040-30 | Sponsor Protocol Number: 202100912 | Start Date*: 2023-03-06 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: An open label pilot study of [18AlF]-Resca-IL2 (Interleukin-2 PET tracer) for positron emission tomography imaging in patients treated with immune checkpoint inhibitors. | ||
Medical condition: patients with stage IV non-small-cell lung carcinoma (NSCLC), renal cell carcinoma (RCC), CSCC, urothelial cell cancer (UCC), and head and neck squamous cell carcinoma (HNSCC), eligible for ICI the... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023355-29 | Sponsor Protocol Number: PO1425 | Start Date*: 2011-05-18 | |||||||||||
Sponsor Name:Papworth Hospital NHS Foundation Trust | |||||||||||||
Full Title: Tyrosine kinase Inhibitors in DysplAsia of Lung epithelium Study 1 | |||||||||||||
Medical condition: High grade dysplasia of the bronchoepithelium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005140-16 | Sponsor Protocol Number: APL2-202 | Start Date*: 2018-07-18 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals | |||||||||||||
Full Title: A Phase IIa, Open Label, Multiple Dose Study to Assess the Safety, Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005629-65 | Sponsor Protocol Number: RG_12-269 | Start Date*: 2014-01-15 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study | |||||||||||||
Medical condition: Chronic Myeloid Leukaemia (CML) in Blast Phase | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004478-80 | Sponsor Protocol Number: Issue1 | Start Date*: 2014-01-08 | |||||||||||||||||||||
Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||
Full Title: XENON AND COOLING THERAPY IN BABIES AT HIGH RISK OF BRAIN INJURY FOLLOWING POOR CONDITION AT BIRTH: A RANDOMISED OUTCOME STUDY (COOLXENON3 STUDY) | |||||||||||||||||||||||
Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001106-23 | Sponsor Protocol Number: APL2-307 | Start Date*: 2019-08-09 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) ES (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005397-34 | Sponsor Protocol Number: Issue1 | Start Date*: 2012-02-24 | |||||||||||||||||||||
Sponsor Name:University Hospital Bristol NHS Foundation Trust | |||||||||||||||||||||||
Full Title: Xenon and cooling therapy in babies at high risk of brain injury following poor condition at birth: Randomised pilot study. (CoolXenon2 study) | |||||||||||||||||||||||
Medical condition: Neonatal hypoxia-ischaemia (HI). There is no exact MedDRA term for this. The closest MedDRA terms matching this are neonatal asphyxia and neonatal hypoxia. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
